vs

Side-by-side financial comparison of Grove Collaborative Holdings, Inc. (GROV) and Health Catalyst, Inc. (HCAT). Click either name above to swap in a different company.

Health Catalyst, Inc. is the larger business by last-quarter revenue ($74.7M vs $42.4M, roughly 1.8× Grove Collaborative Holdings, Inc.). Grove Collaborative Holdings, Inc. runs the higher net margin — -3.7% vs -121.9%, a 118.2% gap on every dollar of revenue. On growth, Health Catalyst, Inc. posted the faster year-over-year revenue change (-6.2% vs -14.3%). Health Catalyst, Inc. produced more free cash flow last quarter ($9.6M vs $-62.0K). Over the past eight quarters, Health Catalyst, Inc.'s revenue compounded faster (-0.0% CAGR vs -11.0%).

Grove Collaborative is a benefit corporation headquartered in San Francisco, with an additional office in Portland, Maine. The company makes and sells its own environmentally friendly home and personal care products under its Grove Co. brand, as well as products from other companies.

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company based in Coral Gables, Florida, United States. The company develops medicines for rare diseases, including the phosphate salt of amifampridine for the treatment of Lambert–Eaton myasthenic syndrome (LEMS). The drug is referred to under the trade name Firdapse, which was approved by the FDA for approved use in children 6 years and older with LEMS in addition to the prior approval for use in adults with LEMS on November 28, 2018. Fir...

GROV vs HCAT — Head-to-Head

Bigger by revenue
HCAT
HCAT
1.8× larger
HCAT
$74.7M
$42.4M
GROV
Growing faster (revenue YoY)
HCAT
HCAT
+8.1% gap
HCAT
-6.2%
-14.3%
GROV
Higher net margin
GROV
GROV
118.2% more per $
GROV
-3.7%
-121.9%
HCAT
More free cash flow
HCAT
HCAT
$9.7M more FCF
HCAT
$9.6M
$-62.0K
GROV
Faster 2-yr revenue CAGR
HCAT
HCAT
Annualised
HCAT
-0.0%
-11.0%
GROV

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
GROV
GROV
HCAT
HCAT
Revenue
$42.4M
$74.7M
Net Profit
$-1.6M
$-91.0M
Gross Margin
53.0%
Operating Margin
-3.7%
-115.3%
Net Margin
-3.7%
-121.9%
Revenue YoY
-14.3%
-6.2%
Net Profit YoY
87.5%
-340.3%
EPS (diluted)
$-0.06
$-1.29

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
GROV
GROV
HCAT
HCAT
Q4 25
$42.4M
$74.7M
Q3 25
$43.7M
$76.3M
Q2 25
$44.0M
$80.7M
Q1 25
$43.5M
$79.4M
Q4 24
$49.5M
$79.6M
Q3 24
$48.3M
$76.4M
Q2 24
$52.1M
$75.9M
Q1 24
$53.5M
$74.7M
Net Profit
GROV
GROV
HCAT
HCAT
Q4 25
$-1.6M
$-91.0M
Q3 25
$-3.0M
$-22.2M
Q2 25
$-3.6M
$-41.0M
Q1 25
$-3.5M
$-23.7M
Q4 24
$-12.6M
$-20.7M
Q3 24
$-1.3M
$-14.7M
Q2 24
$-10.1M
$-13.5M
Q1 24
$-3.4M
$-20.6M
Gross Margin
GROV
GROV
HCAT
HCAT
Q4 25
53.0%
Q3 25
53.3%
52.6%
Q2 25
55.4%
Q1 25
53.0%
Q4 24
52.4%
Q3 24
53.0%
47.5%
Q2 24
53.9%
Q1 24
55.5%
Operating Margin
GROV
GROV
HCAT
HCAT
Q4 25
-3.7%
-115.3%
Q3 25
-6.2%
-22.9%
Q2 25
-7.9%
-46.0%
Q1 25
-8.1%
-25.4%
Q4 24
-16.8%
-22.0%
Q3 24
-14.0%
-17.9%
Q2 24
-13.3%
-20.8%
Q1 24
-1.0%
-30.5%
Net Margin
GROV
GROV
HCAT
HCAT
Q4 25
-3.7%
-121.9%
Q3 25
-6.8%
-29.1%
Q2 25
-8.2%
-50.8%
Q1 25
-8.1%
-29.9%
Q4 24
-25.5%
-26.0%
Q3 24
-2.8%
-19.3%
Q2 24
-19.3%
-17.8%
Q1 24
-6.3%
-27.6%
EPS (diluted)
GROV
GROV
HCAT
HCAT
Q4 25
$-0.06
$-1.29
Q3 25
$-0.08
$-0.32
Q2 25
$-0.10
$-0.59
Q1 25
$-0.10
$-0.35
Q4 24
$-0.34
$-0.33
Q3 24
$-0.04
$-0.24
Q2 24
$-0.28
$-0.23
Q1 24
$-0.10
$-0.35

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
GROV
GROV
HCAT
HCAT
Cash + ST InvestmentsLiquidity on hand
$8.5M
$95.7M
Total DebtLower is stronger
$153.3M
Stockholders' EquityBook value
$-17.0M
$245.8M
Total Assets
$53.1M
$502.6M
Debt / EquityLower = less leverage
0.62×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
GROV
GROV
HCAT
HCAT
Q4 25
$8.5M
$95.7M
Q3 25
$8.9M
$91.5M
Q2 25
$10.0M
$97.3M
Q1 25
$9.6M
$342.0M
Q4 24
$19.6M
$392.0M
Q3 24
$50.8M
$387.3M
Q2 24
$78.8M
$308.3M
Q1 24
$77.8M
$327.8M
Total Debt
GROV
GROV
HCAT
HCAT
Q4 25
$153.3M
Q3 25
$153.1M
Q2 25
$153.0M
Q1 25
$382.9M
Q4 24
$382.4M
Q3 24
$32.2M
$345.0M
Q2 24
Q1 24
Stockholders' Equity
GROV
GROV
HCAT
HCAT
Q4 25
$-17.0M
$245.8M
Q3 25
$-16.1M
$331.9M
Q2 25
$-14.0M
$347.5M
Q1 25
$-11.6M
$376.8M
Q4 24
$-8.5M
$365.2M
Q3 24
$1.5M
$355.0M
Q2 24
$686.0K
$357.0M
Q1 24
$7.5M
$357.2M
Total Assets
GROV
GROV
HCAT
HCAT
Q4 25
$53.1M
$502.6M
Q3 25
$54.6M
$587.1M
Q2 25
$57.8M
$616.2M
Q1 25
$59.8M
$891.5M
Q4 24
$65.0M
$858.9M
Q3 24
$105.2M
$813.0M
Q2 24
$131.8M
$691.7M
Q1 24
$137.9M
$695.1M
Debt / Equity
GROV
GROV
HCAT
HCAT
Q4 25
0.62×
Q3 25
0.46×
Q2 25
0.44×
Q1 25
1.02×
Q4 24
1.05×
Q3 24
21.16×
0.97×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
GROV
GROV
HCAT
HCAT
Operating Cash FlowLast quarter
$-29.0K
$9.9M
Free Cash FlowOCF − Capex
$-62.0K
$9.6M
FCF MarginFCF / Revenue
-0.1%
12.9%
Capex IntensityCapex / Revenue
0.1%
0.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-8.1M
$-697.0K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
GROV
GROV
HCAT
HCAT
Q4 25
$-29.0K
$9.9M
Q3 25
$-1.0M
$-464.0K
Q2 25
$987.0K
$-9.0M
Q1 25
$-6.9M
$280.0K
Q4 24
$270.0K
$-3.5M
Q3 24
$750.0K
$6.2M
Q2 24
$1.6M
$1.6M
Q1 24
$-12.4M
$10.3M
Free Cash Flow
GROV
GROV
HCAT
HCAT
Q4 25
$-62.0K
$9.6M
Q3 25
$-1.2M
$-719.0K
Q2 25
$556.0K
$-9.2M
Q1 25
$-7.4M
$-390.0K
Q4 24
$-95.0K
$-3.9M
Q3 24
$264.0K
$5.5M
Q2 24
$1.2M
$1.3M
Q1 24
$-12.9M
$10.1M
FCF Margin
GROV
GROV
HCAT
HCAT
Q4 25
-0.1%
12.9%
Q3 25
-2.7%
-0.9%
Q2 25
1.3%
-11.4%
Q1 25
-17.0%
-0.5%
Q4 24
-0.2%
-4.9%
Q3 24
0.5%
7.2%
Q2 24
2.3%
1.7%
Q1 24
-24.1%
13.5%
Capex Intensity
GROV
GROV
HCAT
HCAT
Q4 25
0.1%
0.4%
Q3 25
0.4%
0.3%
Q2 25
1.0%
0.3%
Q1 25
1.2%
0.8%
Q4 24
0.7%
0.5%
Q3 24
1.0%
0.9%
Q2 24
0.7%
0.4%
Q1 24
1.0%
0.3%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

GROV
GROV

Third Party Products$23.4M55%
Grove Brands$19.0M45%

HCAT
HCAT

Recurring Technology$51.9M69%
Professional Services$22.8M31%

Related Comparisons